drugset
drugset / Trial / NCT01022853

Combination of BI6727 (Volasertib) and BIBF1120 in Solid Tumors

NCT01022853 ↗

Phase 1 Completed 30 enrolled Boehringer Ingelheim
NaSingle-groupOpen-labelTreatment

Summary

The primary objective of the current study is to investigate the Maximum Tolerated Dose (MTD) in terms of safety and tolerability of BI 6727 in combination with fixed dose BIBF 1120, in patients with advanced or metastatic solid tumours.

Timeline

Start
2009-12
Primary completion
2013-02
Completion
2013-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Volasertib Small molecule — Intravenous
Background Nintedanib Small molecule — Oral

Indications

neoplasm